Skip to main content
. 2019 Nov 11;176(Suppl 1):S297–S396. doi: 10.1111/bph.14752
Nomenclature http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1385 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1386 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1387 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1388 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1389 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1390
HGNC, UniProt https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:435, http://www.uniprot.org/uniprot/P09917 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:430, http://www.uniprot.org/uniprot/O75342 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:429, http://www.uniprot.org/uniprot/P18054 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:433, http://www.uniprot.org/uniprot/P16050 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:434, http://www.uniprot.org/uniprot/O15296 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13743, http://www.uniprot.org/uniprot/Q9BYJ1
EC number http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.34: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214 + H2O http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101 http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 => http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481 http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482 http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052 + O2 => 13S‐HPODE http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 + O2 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482 http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.‐
Substrates – http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5222 – – – –
Endogenous substrates http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391 – – – – http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101
Endogenous activators http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5183 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:436, http://www.uniprot.org/uniprot/P20292) – – – – –
Endogenous inhibitors Protein kinase A‐mediated phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/15280375?dopt=AbstractPlus] – – – – –
Inhibitors – – – http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10263 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/24672829?dopt=AbstractPlus] http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8750 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/17656086?dopt=AbstractPlus] –
Selective inhibitors http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5169 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/15197110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9054 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/20378715?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/1848634?dopt=AbstractPlus] – http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8752 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/24393039?dopt=AbstractPlus] http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8751 (pK i >8) [http://www.ncbi.nlm.nih.gov/pubmed/20866075?dopt=AbstractPlus] – –
Comments FLAP activity can be inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2655 [http://www.ncbi.nlm.nih.gov/pubmed/2300173?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5148 [http://www.ncbi.nlm.nih.gov/pubmed/8381000?dopt=AbstractPlus] leading to a selective inhibition of 5‐LOX activity – – – Inhibited by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10264 (pKi 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/25111178?dopt=AbstractPlus]. E‐LOX metabolises the product from the 12R‐lipoxygenase (12R‐HPETE) to a specific epoxyalcohol compound [http://www.ncbi.nlm.nih.gov/pubmed/12881489?dopt=AbstractPlus].